LIPAC Oncology Announces Appointment of Josh Hamermesh to the Board of Directors

LIPAC Oncology Announces Appointment of Josh Hamermesh to the Board of Directors
Industry Veteran Brings More Than 20 Years of Biotech Leadership Experience
News provided by
Share this article
Share this article
MENLO PARK, Calif., May 6, 2021 /PRNewswire/ -- LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Josh Hamermesh as an independent board director.
"Josh is a noted expert in driving and supporting the growth of innovative companies thanks to his two decades of leadership experience in the biotechnology industry," said Will Robberts, President of LIPAC Oncology. "We welcome Josh to the Board and look forward to his insights and contributions around both corporate and business development, strategy and commercialization as we continue to advance our oncology pipeline and build our business."

Related Keywords

Sherri Spear ,Josh Hamermesh ,Leo Vartorella ,Molecular Insight Pharmaceuticals Inc ,Harvard Business School ,Amherst College ,Corporate Development At Pervasis Therapeutics Inc ,Neurohealing Pharmaceuticals Inc ,Corporate Development At Infinity Pharmaceuticals Inc ,Locust Walk Partners Inc ,Gamida Cell Ltd ,Will Robberts ,Chief Business Officer ,Gamida Cell ,Senior Vice President ,Locust Walk Partners ,Locust Walk ,Vice President ,Corporate Development ,Infinity Pharmaceuticals ,Pervasis Therapeutics ,Molecular Insight Pharmaceuticals ,Neurohealing Pharmaceuticals ,Harvard Business ,ஷெர்ரி ஈட்டி ,ஹார்வர்ட் வணிக பள்ளி ,மஹேர்ஸ்ட கல்லூரி ,தலைமை வணிக அதிகாரி ,மூத்தவர் துணை ப்ரெஸிடெஂட் ,வெட்டுக்கிளி நட ,துணை ப்ரெஸிடெஂட் ,பெருநிறுவன வளர்ச்சி ,முடிவிலி மருந்துகள் ,மூலக்கூறு நுண்ணறிவு மருந்துகள் ,ஹார்வர்ட் வணிக ,